Year: 2023

news_6

Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

image_1-2

Traveloka Impact Study by PwC: SEA’s leading travel platform propels global exposure and growth for Indonesia’s tourism ecosystem

PwC research reveals Traveloka, Indonesia’s tech success story, aided post-pandemic recovery by contributing approximately USD10 billion to Indonesia’s GDP SINGAPORE...